SAN DIEGO, July 10 /PRNewswire-FirstCall/ -- PURE Bioscience announced today that its distributor in Brazil has obtained national regulatory approval, recently published in the Brazilian Official Gazette No. 113, for its silver dihydrogen citrate (SDC)-based disinfectant, “Desinfetante de Uso Geral LFE 100SX.”
(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)
In March 2007, under the terms of a multi-year contract, PURE had granted a license to market and sell its silver dihydrogen citrate (SDC)-based products in Brazil to privately held Life Biociencias S/A of Apucarana, Parana in Brazil (Lifebio), a company of Grupo Nilson Ribeiro, together in a joint venture with privately held PCI International, Inc. of Lafayette, Louisiana (PCI).
Under the agreement, PURE sells concentrate to Lifebio/PCI for blending, packaging and distribution of non-pharmaceutical SDC-based antimicrobial products. Lifebio/PCI has constructed a facility in Apucarana, Parana dedicated to blending and packaging SDC concentrate into hard surface disinfectant. Lifebio is now poised to begin marketing and sales of its SDC-based 100SX General Disinfectant.
L. Felippe C. De Castro, President and CEO of PCI stated, “SDC stands on the cutting edge of innovation by providing unmatched efficacy and safety in the marketplace, and at the same time, replacing many toxic chemicals currently in use. Our partnership with PURE Bioscience brings needed solutions and presents even greater opportunities within Brazil.”
Dr. Nilson Umberto Sacchelli Ribeiro, President of Lifebio and a Director of Grupo Nilson Ribeiro, added, “Our marketing efforts are well underway and our manufacturing facility is staffed and ready to begin volume production of SDC-based disinfectant. Our initial targets -- with whom we have been working closely -- include federal, state and municipal governments, hospitals and clinics, as well as other institutional users.
“More importantly, as a platform technology, SDC provides a broad range of applications for use in farming, ranching, food processing, packing and distribution and healthcare. To that end, our joint development programs with the Brazilian ministries of Health and Agriculture are well underway and are making solid progress. SDC can drive solutions that bring increased productivity, efficiency and growth that cut across virtually all geographic and industry sectors within Brazil.”
Michael L. Krall, President and CEO of PURE Bioscience commented, “Receiving regulatory approval is a key milestone for our partners, who will now begin to introduce product into the world’s ninth largest economy. Broadening SDC commercialization for use in health, food and water applications gives testimony to Lifebio’s foresight in planning and can serve as a model for the integrated utilization and multiple benefits of SDC-based solutions.”
About PCI International, Inc.
PCI International, Inc. was established in 1981 as an international consulting, trading and government relations firm, with highly specialized expertise in international trade and economic development. PCI is always prepared to meet the industry’s changing needs and toughest challenges. PCI was formed to provide substantial counsel in international trade opportunities, to develop International projects and to pursue its clients best interests in any given market and its government, specifically in the country of Brazil.
About Life Biociencias S/A
Lifebio, established solely to develop and promote silver dihydrogen citrate as a platform technology in Brazil, is a company of Grupo Nilson Ribeiro also headquartered in Apucarana, Parana in Brazil. Other companies under the Grupo Nilson Ribeiro umbrella include N.A.R. Agropecuaria, Europe Meat S.p.A., K.Log, Companhia Italo-Brasileira de Produtos Alimenticios, Araguaina Industrial Exportadora de Produtos Alimenticios, King Meat Alimentos, Agua Mineral Maceratti S/A, Reines -- SRM Pet Food Industrial, SRM America, SRM Brasil Participacoes, Frizz Midia, Parana Logistica, NUSR Investimentos e Participacoes, JJ Participacoes Empresariais, Tecnocol Tecnologia Industrial e Comercial, Grafinorte S.A., Radio Nova AM 910, Tribuna do Norte and Tribuna 89.5 FM.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company’s current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
CONTACT: investors, Paul G. Henning, Vice President of Cameron Associates,
+1-212-554-5462, paul@cameronassoc.com; or media, Karen Sparks of Mentus,
+1-858-455-5500, ext. 275, karen@mentus.com, both for PURE Bioscience
Web site: http://www.purebio.com/
